Division of Urology, Department of Surgical Oncology, University of Toronto, Princess Margaret Hospital, 610 University Avenue 3-130, Toronto, ON M5G 2M9, Canada.
Nat Rev Urol. 2010 Oct;7(10):543-51. doi: 10.1038/nrurol.2010.143.
The role of imaging in treatment decision-making for patients with prostate cancer is to characterize the cancer already diagnosed on biopsy, to determine tumor location, to assess tumor volume, and to exclude more-extensive disease. MRI is currently the most established imaging modality for this purpose, with the highest sensitivity and specificity for detection and staging of prostate tumors. The development and wider adoption of active surveillance and focal treatment approaches would also benefit from accurate localization of cancer. As such, 3 T MRI and multiparametric approaches are being developed as tools for the localization and staging of prostate cancer. Men wishing to commence or remain on active surveillance might benefit by having larger cancers identified before embarking on this management strategy. MRI might have its greatest role in patients where there is a discrepancy between PSA and biopsy results suggesting a potential missed prostate tumor.
影像在前列腺癌患者的治疗决策中的作用是对活检已诊断的癌症进行特征分析，确定肿瘤位置，评估肿瘤体积，并排除更广泛的疾病。MRI 目前是为此目的最成熟的影像学手段，具有最高的敏感性和特异性，可用于检测和分期前列腺肿瘤。主动监测和局部治疗方法的发展和更广泛的应用也将受益于癌症的准确定位。因此，3T MRI 和多参数方法正在被开发为定位和分期前列腺癌的工具。希望开始或继续接受主动监测的男性可能会受益于在采用这种管理策略之前，发现更大的癌症。在 PSA 和活检结果之间存在差异，提示可能存在潜在的前列腺肿瘤的情况下，MRI 可能具有最大的作用。
